CLINICAL_TRIALS
ClinicalTrials.gov record update
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04739800
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:56.888099+00:00
- Published At
- 2024-06-18T00:00:00+00:00
- Record Updated At
- 2026-04-13
- Results Posted At
- 2024-06-18
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Fallopian Tube Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Platinum-Refractory Fallopian Tube Carcinoma", "Platinum-Refractory Ovarian Carcinoma", "Platinum-Refractory Primary Peritoneal Carcinoma", "Recurrent Fallopian Tube Clear Cell Adenocarcinoma", "Recurrent Fallopian Tube Endometrioid Adenocarcinoma", "Recurrent Fallopian Tube High Grade Serous Adenocarcinoma", "Recurrent Fallopian Tube Mucinous Adenocarcinoma", "Recurrent Fallopian Tube Transitional Cell Carcinoma", "Recurrent Fallopian Tube Undifferentiated Carcinoma", "Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Recurrent Ovarian Low Grade Serous Adenocarcinoma", "Recurrent Ovarian Mucinous Adenocarcinoma", "Recurrent Ovarian Seromucinous Carcinoma", "Recurrent Ovarian Transitional Cell Carcinoma", "Recurrent Ovarian Undifferentiated Carcinoma", "Recurrent Platinum-Resistant Fallopian Tube Carcinoma", "Recurrent Platinum-Resistant Ovarian Carcinoma", "Recurrent Platinum-Resistant Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Clear Cell Adenocarcinoma", "Recurrent Primary Peritoneal Endometrioid Adenocarcinoma", "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma", "Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma", "Recurrent Primary Peritoneal Transitional Cell Carcinoma", "Recurrent Primary Peritoneal Undifferentiated Carcinoma", "Refractory Fallopian Tube Clear Cell Adenocarcinoma", "Refractory Fallopian Tube Endometrioid Adenocarcinoma", "Refractory Fallopian Tube High Grade Serous Adenocarcinoma", "Refractory Fallopian Tube Mucinous Adenocarcinoma", "Refractory Fallopian Tube Transitional Cell Carcinoma", "Refractory Fallopian Tube Undifferentiated Carcinoma", "Refractory Low Grade Fallopian Tube Serous Adenocarcinoma", "Refractory Ovarian Clear Cell Adenocarcinoma", "Refractory Ovarian Endometrioid Adenocarcinoma", "Refractory Ovarian High Grade Serous Adenocarcinoma", "Refractory Ovarian Low Grade Serous Adenocarcinoma", "Refractory Ovarian Mucinous Adenocarcinoma", "Refractory Ovarian Seromucinous Carcinoma", "Refractory Ovarian Transitional Cell Carcinoma", "Refractory Ovarian Undifferentiated Carcinoma", "Refractory Primary Peritoneal Clear Cell Adenocarcinoma", "Refractory Primary Peritoneal Endometrioid Adenocarcinoma", "Refractory Primary Peritoneal High Grade Serous Adenocarcinoma", "Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma", "Refractory Primary Peritoneal Transitional Cell Carcinoma", "Refractory Primary Peritoneal Undifferentiated Carcinoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-13"- protocolSection.identificationModule.nctId
"NCT04739800"- protocolSection.identificationModule.officialTitle
"A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2024-06-18"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.